SOURCE-LINKED STUDY SUMMARY
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- Phase 3 randomized trial comparing two semaglutide doses with placebo, alongside lifestyle intervention, for weight management.
- Who / model studied
- 1210 adults with overweight or obesity and type 2 diabetes, treated for 68 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- In the main higher-dose comparison, average weight fell 9·6% versus 3·4% with placebo, and 68·8% versus 28·5% lost at least 5%, the two primary outcomes. Digestive adverse events occurred in 63·5% with the higher dose, 57·5% with the lower dose and 34·3% with placebo, mostly mild or moderate.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(21)00213-0